Levodopa/carbidopa subcutaneous - NeuroDerm
Alternative Names: Carbidopa/levodopa subcutaneous - NeuroDerm; ND-0612; ND-0612H; ND-0612L; ND-0680Latest Information Update: 21 Jun 2024
At a glance
- Originator NeuroDerm
- Class Antiasthmatics; Antiparkinsonians; Aromatic amino acids; Catecholamines; Hydrazines; Small molecules
- Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Parkinson's disease
Most Recent Events
- 11 Jun 2024 Mitsubishi Tanabe Pharma Corporation receives complete response letter from the FDA for levodopa/carbidopa in Parkinson’s disease
- 13 Apr 2024 Interim efficacy data from the phase-IIb BeyoND trial in Parkinson's disease presented at the 76th Annual Meeting of the American Academy of Neurology (AAN-2024)
- 13 Apr 2024 Updated efficacy data from a phase II trial in Parkinson's disease presented at the 76th Annual Meeting of the American Academy of Neurology 2024 (AAN-2024)